Stomach Cancer Research
For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting ConsequencesPosted:
In a recent study, more than 90% of people who’d had their stomach surgically removed to prevent cancer experienced a least one chronic complication 2 years out from their surgery. For some, the complications are life altering.
FDA Amends Approval of Pembrolizumab to Treat Stomach and Esophageal Junction CancerPosted:
FDA has changed its 2021 approval of pembrolizumab (Keytruda) along with trastuzumab (Herceptin) and chemotherapy for treating HER2-positive stomach or GEJ cancer. The agency also announced a new approval of pembrolizumab for HER2-negative forms of these same cancers.
Nivolumab Improves Survival for Some Patients with Advanced Stomach CancerPosted:
For some people with advanced stomach cancer, the drug nivolumab (Opdivo) plus chemotherapy may improve how long they live, results from a large clinical trial show. The trial also included patients with gastric cancers that involve the esophagus.
Incidence of Cancers of the Lower Stomach Increasing among Younger AmericansPosted:
A type of cancer that occurs in the lower stomach has been increasing among some Americans under the age of 50, even though in the general population the incidence of all stomach cancers has been declining for decades, according to a new study.
Pembrolizumab Secures FDA Approval in Stomach CancerPosted:
The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab (Keytruda®) for use in patients with advanced gastric (stomach) cancer that is PD-L1 positive.
TCGA researchers identify four subtypes of stomach cancerPosted:
Stomach cancers fall into four distinct molecular subtypes, researchers with The Cancer Genome Atlas (TCGA) Network have found. Scientists report that this discovery could change how researchers think about developing treatments for stomach cancer, also called gastric cancers or gastric adenocarcinomas.